Context Therapeutics (CNTX) News Today $0.87 -0.02 (-2.25%) Closing price 04:00 PM EasternExtended Trading$0.86 -0.01 (-0.91%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Context Therapeutics Reports Q2 2025 Financial ResultsAugust 22 at 11:53 AM | msn.comContext Therapeutics Inc. (NASDAQ:CNTX) Receives $5.25 Average Price Target from AnalystsAugust 20, 2025 | americanbankingnews.comContext Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Rating of "Buy" from BrokeragesAugust 16, 2025 | marketbeat.comWilliam Blair Has Pessimistic Outlook of CNTX Q3 EarningsAugust 11, 2025 | marketbeat.comContext Therapeutics Highlights Pipeline Progress, Reports $8.8M Loss in Q2August 8, 2025 | msn.comHC Wainwright Lowers Context Therapeutics (NASDAQ:CNTX) Price Target to $4.00August 8, 2025 | marketbeat.comContext Therapeutics' (CNTX) Buy Rating Reiterated at D. Boral CapitalAugust 8, 2025 | marketbeat.comContext Therapeutics Reports Second Quarter 2025 Operating and Financial ResultsAugust 6, 2025 | globenewswire.comContext Therapeutics (CNTX) to Release Earnings on WednesdayJuly 31, 2025 | marketbeat.comContext Therapeutics Presents CTIM-76 Phase 1 Trial in Progress at ASCO 2025July 25, 2025 | msn.comContext Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of "Buy" from AnalystsJuly 21, 2025 | marketbeat.comContext Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Recommendation of "Buy" by BrokeragesJune 26, 2025 | marketbeat.comContext Therapeutics (NASDAQ:CNTX) Earns Overweight Rating from Piper SandlerJune 26, 2025 | marketbeat.comContext Therapeutics Approves Reverse Stock Split AmendmentJune 12, 2025 | tipranks.comCo-Founder of Context Therapeutics Martin Lehr Buys 10% More SharesJune 11, 2025 | finance.yahoo.comContext Therapeutics Inc. (NASDAQ:CNTX) Insider Alex C. Levit Purchases 20,000 SharesJune 11, 2025 | insidertrades.comContext Therapeutics: Undervalued Cancer FighterJune 10, 2025 | seekingalpha.comInsider Buying: Context Therapeutics Inc. (NASDAQ:CNTX) Insider Buys 20,000 Shares of StockJune 10, 2025 | marketbeat.comContext Therapeutics Inc. (NASDAQ:CNTX) CFO Acquires $25,606.40 in StockJune 10, 2025 | marketbeat.comInsider Buying: Context Therapeutics Inc. (NASDAQ:CNTX) CEO Buys 100,000 Shares of StockJune 10, 2025 | marketbeat.comContext Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO MeetingJune 2, 2025 | globenewswire.comContext Therapeutics Inc.: Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical OfficerMay 29, 2025 | finanznachrichten.deContext Therapeutics Inc. Appoints Dr. Karen Chagin as Chief Medical OfficerMay 29, 2025 | quiverquant.comQContext Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical OfficerMay 29, 2025 | globenewswire.comVelan Capital Investment Management LP Has $94,000 Stock Position in Context Therapeutics Inc. (NASDAQ:CNTX)May 22, 2025 | marketbeat.comMPM Bioimpact LLC Buys New Stake in Context Therapeutics Inc. (NASDAQ:CNTX)May 16, 2025 | marketbeat.comContext Therapeutics Inc. (NASDAQ:CNTX) Given Average Rating of "Buy" by BrokeragesMay 15, 2025 | marketbeat.comWilliam Blair Has Positive Outlook of CNTX FY2025 EarningsMay 13, 2025 | marketbeat.comResearch Analysts Offer Predictions for CNTX Q2 EarningsMay 13, 2025 | marketbeat.comContext Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 12, 2025 | globenewswire.comContext Therapeutics Reports Q1 2025 Financial Results and Clinical ProgressMay 11, 2025 | msn.comD. Boral Capital Reiterates "Buy" Rating for Context Therapeutics (NASDAQ:CNTX)May 10, 2025 | marketbeat.comCONTEXT THERAPEUTICS Earnings Results: $CNTX Reports Quarterly EarningsMay 9, 2025 | nasdaq.comContext Therapeutics (CNTX) Expected to Announce Earnings on WednesdayMay 9, 2025 | marketbeat.comContext Therapeutics Reports First Quarter 2025 Operating and Financial ResultsMay 7, 2025 | globenewswire.comContext Therapeutics Inc.: Context Therapeutics Announces Chief Medical Officer TransitionMay 6, 2025 | finanznachrichten.deContext Therapeutics Announces Chief Medical Officer TransitionMay 5, 2025 | tmcnet.comContext Therapeutics Announces Chief Medical Officer TransitionMay 5, 2025 | globenewswire.comAllostery Investments LP Purchases New Position in Context Therapeutics Inc. (NASDAQ:CNTX)May 4, 2025 | marketbeat.comContext Therapeutics Showcases Promising CT-95 Data at AACR Annual MeetingMay 4, 2025 | msn.comEquities Analysts Issue Forecasts for CNTX Q2 EarningsMay 3, 2025 | marketbeat.comAnalysts Issue Forecasts for CNTX Q1 EarningsMay 2, 2025 | marketbeat.comContext Therapeutics (NASDAQ:CNTX) Receives "Outperform" Rating from William BlairMay 1, 2025 | marketbeat.comD. Boral Capital Reaffirms Buy Rating for Context Therapeutics (NASDAQ:CNTX)May 1, 2025 | marketbeat.comContext Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual MeetingApril 30, 2025 | globenewswire.comBlue Owl Capital Holdings LP Acquires 946,638 Shares of Context Therapeutics Inc. (NASDAQ:CNTX)April 26, 2025 | marketbeat.comQ1 Earnings Forecast for CNTX Issued By William BlairApril 25, 2025 | marketbeat.comWilliam Blair starts Context Therapeutics stock with OutperformApril 23, 2025 | uk.investing.comContext Therapeutics (NASDAQ:CNTX) Now Covered by William BlairApril 23, 2025 | marketbeat.comWilliam Blair Initiates Coverage of Context Therapeutics (CNTX) with Outperform RecommendationApril 22, 2025 | msn.com Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address CNTX Media Mentions By Week CNTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CNTX News Sentiment▼0.000.70▲Average Medical News Sentiment CNTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CNTX Articles This Week▼22▲CNTX Articles Average Week Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies FHTX News AVIR News MREO News LFCR News DBVT News EDIT News ANNX News NMRA News ALMS News IMMP News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CNTX) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access